BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61:746-759. [PMID: 19389436 DOI: 10.1016/j.addr.2009.04.004] [Cited by in Crossref: 324] [Cited by in F6Publishing: 282] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Tsai LR, Chen MH, Chien CT, Chen MK, Lin FS, Lin KM, Hwu YK, Yang CS, Lin SY. A single-monomer derived linear-like PEI-co-PEG for siRNA delivery and silencing. Biomaterials 2011;32:3647-53. [PMID: 21324524 DOI: 10.1016/j.biomaterials.2011.01.059] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
2 Faraz M, Herdenberg C, Holmlund C, Henriksson R, Hedman H. A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors. J Biol Chem 2018;293:3421-35. [PMID: 29317492 DOI: 10.1074/jbc.M117.807487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
3 Gerami M, Emadi-Baygi M, Eshghi M, Elahian F, Heidari R, Hosseinzadeh M. Synthetic Biology Based on Genetic Logic Circuit, Using the Expression of Drug Resistance, BCRP Pump in MCF-7 Cancer Cell Line. Iran J Pharm Res 2020;19:195-205. [PMID: 33680022 DOI: 10.22037/ijpr.2020.111970.13459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Zhang Z, Li Z, Deng M, Liu B, Xin X, Zhao Z, Zhang Y, Lv Q. Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer. Oncol Rep 2020;43:965-74. [PMID: 32020211 DOI: 10.3892/or.2020.7471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Parsel SM, Grandis JR, Thomas SM. Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 2016;35:3217-26. [PMID: 26592450 DOI: 10.1038/onc.2015.424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Zhang RX, Yan XB, Gu YH, Huang D, Gan L, Han R, Huang LH. Gene silencing of NR2B-containing NMDA receptor by intrathecal injection of short hairpin RNA reduces formalin-induced nociception in C57BL/6 mouse. Int J Neurosci 2013;123:650-6. [PMID: 23528046 DOI: 10.3109/00207454.2013.789873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Duncan JR. Current perspectives on the neurobiology of drug addiction: a focus on genetics and factors regulating gene expression. ISRN Neurol 2012;2012:972607. [PMID: 23097719 DOI: 10.5402/2012/972607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Liu Z, Wang S, Tapeinos C, Torrieri G, Känkänen V, El-Sayed N, Python A, Hirvonen JT, Santos HA. Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines. Adv Drug Deliv Rev 2021;174:576-612. [PMID: 34019958 DOI: 10.1016/j.addr.2021.05.018] [Reference Citation Analysis]
9 Murray EJ, Burden F, Horscroft N, Smith-Burchnell C, Westby M. Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells. Antimicrob Agents Chemother 2011;55:4311-9. [PMID: 21709085 DOI: 10.1128/AAC.00644-11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Böldicke T, Somplatzki S, Sergeev G, Mueller PP. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum. Methods 2012;56:338-50. [PMID: 22037249 DOI: 10.1016/j.ymeth.2011.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Zou J, Li XL, Shi ZM, Xue JF. Effects of C-myc gene silencing on interleukin-1β-induced rat chondrocyte cell proliferation, apoptosis and cytokine expression. J Bone Miner Metab 2018;36:286-96. [PMID: 28616752 DOI: 10.1007/s00774-017-0845-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Bellefroid C, Lechanteur A, Evrard B, Piel G. Lipid gene nanocarriers for the treatment of skin diseases: Current state-of-the-art. European Journal of Pharmaceutics and Biopharmaceutics 2019;137:95-111. [DOI: 10.1016/j.ejpb.2019.02.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
13 Her YF, Nelson-Holte M, Maher LJ 3rd. Oxygen concentration controls epigenetic effects in models of familial paraganglioma. PLoS One 2015;10:e0127471. [PMID: 25985299 DOI: 10.1371/journal.pone.0127471] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
14 Forbes DC, Peppas NA. Oral delivery of small RNA and DNA. J Control Release 2012;162:438-45. [PMID: 22771979 DOI: 10.1016/j.jconrel.2012.06.037] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
15 Hu Y, Shen Y, Ji B, Yin S, Ren X, Chen T, Ma Y, Zhang Z, Zhang Y. Liver-specific gene therapy of hepatocellular carcinoma by targeting human telomerase reverse transcriptase with pegylated immuno-lipopolyplexes. Eur J Pharm Biopharm 2011;78:320-5. [PMID: 21220007 DOI: 10.1016/j.ejpb.2010.12.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
16 Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. PDX1 associated therapy in translational medicine. Ann Transl Med 2016;4:214. [PMID: 27386488 DOI: 10.21037/atm.2016.03.51] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
17 Devulapally R, Paulmurugan R. Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6:40-60. [PMID: 23996830 DOI: 10.1002/wnan.1242] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
18 Xiu M, Wang Y, Li B, Wang X, Xiao F, Chen S, Zhang L, Zhou B, Hua F. The Role of Notch3 Signaling in Cancer Stemness and Chemoresistance: Molecular Mechanisms and Targeting Strategies. Front Mol Biosci 2021;8:694141. [PMID: 34195229 DOI: 10.3389/fmolb.2021.694141] [Reference Citation Analysis]
19 Rothschild SI. microRNA therapies in cancer. Mol Cell Ther. 2014;2:7. [PMID: 26056576 DOI: 10.1186/2052-8426-2-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
20 Kumar A, Panda SK, Durgapal H, Acharya SK, Rehman S, Kar UK. Inhibition of Hepatitis E virus replication using short hairpin RNA (shRNA). Antiviral Res 2010;85:541-50. [PMID: 20105445 DOI: 10.1016/j.antiviral.2010.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Ebrahimian M, Taghavi S, Mokhtarzadeh A, Ramezani M, Hashemi M. Co-delivery of Doxorubicin Encapsulated PLGA Nanoparticles and Bcl-xL shRNA Using Alkyl-Modified PEI into Breast Cancer Cells. Appl Biochem Biotechnol 2017;183:126-36. [DOI: 10.1007/s12010-017-2434-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
22 Xiao X, Gang Y, Wang H, Wang J, Zhao L, Xu L, Liu Z. Double-stranded RNA transcribed from vector-based oligodeoxynucleotide acts as transcription factor decoy. Biochem Biophys Res Commun 2015;457:221-6. [PMID: 25550185 DOI: 10.1016/j.bbrc.2014.12.091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Arima H, Motoyama K, Irie T. Recent Findings on Safety Profiles of Cyclodextrins, Cyclodextrin Conjugates, and Polypseudorotaxanes. In: Bilensoy E, editor. Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine. Hoboken: John Wiley & Sons, Inc.; 2011. pp. 91-122. [DOI: 10.1002/9780470926819.ch5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
24 Kolanthai E, Fu Y, Kumar U, Babu B, Venkatesan AK, Liechty KW, Seal S. Nanoparticle mediated RNA delivery for wound healing. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1741. [PMID: 34369096 DOI: 10.1002/wnan.1741] [Reference Citation Analysis]
25 Wich PR, Fréchet JMJ. Degradable Dextran Particles for Gene Delivery Applications. Aust J Chem 2012;65:15. [DOI: 10.1071/ch11370] [Cited by in Crossref: 16] [Article Influence: 1.8] [Reference Citation Analysis]
26 Seraj S, Lee J, Ahn HJ. Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: Long-term silencing and anticancer effects in vivo. Biochemical Pharmacology 2019;166:192-202. [DOI: 10.1016/j.bcp.2019.05.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
27 Goldsmith M, Mizrahy S, Peer D. Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine (Lond) 2011;6:1771-85. [PMID: 22122585 DOI: 10.2217/nnm.11.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
28 McCrudden CM, McCarthy HO. Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet 2014;7:209-20. [PMID: 25419154 DOI: 10.2147/TACG.S54992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
29 Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12:492-503. [PMID: 20544328 DOI: 10.1208/s12248-010-9210-4] [Cited by in Crossref: 471] [Cited by in F6Publishing: 421] [Article Influence: 42.8] [Reference Citation Analysis]
30 Lam JK, Chow MY, Zhang Y, Leung SW. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids 2015;4:e252. [PMID: 26372022 DOI: 10.1038/mtna.2015.23] [Cited by in Crossref: 368] [Cited by in F6Publishing: 328] [Article Influence: 61.3] [Reference Citation Analysis]
31 Guo J, Evans JC, O’driscoll CM. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer? Trends in Molecular Medicine 2013;19:250-61. [DOI: 10.1016/j.molmed.2013.02.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
32 Nakashima N, Liu D, Huang CL, Ueno M, Zhang X, Yokomise H. Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer 2012;76:228-34. [PMID: 22070884 DOI: 10.1016/j.lungcan.2011.10.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
33 Antonelli A, La Motta C. Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells. Med Res Rev 2017;37:1299-317. [PMID: 28586525 DOI: 10.1002/med.21448] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
34 Arima H, Motoyama K, Higashi T. Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA. Pharmaceuticals (Basel) 2011;5:61-78. [PMID: 24288043 DOI: 10.3390/ph5010061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
35 Xiang D, Shigdar S, Qiao G, Wang T, Kouzani AZ, Zhou SF, Kong L, Li Y, Pu C, Duan W. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics 2015;5:23-42. [PMID: 25553096 DOI: 10.7150/thno.10202] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 20.3] [Reference Citation Analysis]
36 Novotná E, Tichý A, Pejchal J, Lukášová E, Salovská B, Vávrová J. DNA-dependent protein kinase and its inhibition in support of radiotherapy. Int J Radiat Biol 2013;89:416-23. [PMID: 23362996 DOI: 10.3109/09553002.2013.767993] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
37 Singh Y, Tomar S, Khan S, Meher JG, Pawar VK, Raval K, Sharma K, Singh PK, Chaurasia M, Surendar Reddy B, Chourasia MK. Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes. J Control Release 2015;220:368-87. [PMID: 26528900 DOI: 10.1016/j.jconrel.2015.10.050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
38 Zilio S, Vella JL, De la Fuente AC, Daftarian PM, Weed DT, Kaifer A, Marigo I, Leone K, Bronte V, Serafini P. 4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. J Immunol 2017;198:4166-77. [PMID: 28396317 DOI: 10.4049/jimmunol.1600833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
39 Mohan Kumar D, Lin M, Xiong Q, Webber MJ, Kural C, Rikihisa Y. EtpE Binding to DNase X Induces Ehrlichial Entry via CD147 and hnRNP-K Recruitment, Followed by Mobilization of N-WASP and Actin. mBio 2015;6:e01541-15. [PMID: 26530384 DOI: 10.1128/mBio.01541-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
40 Mantha N, Das SK, Das NG. RNAi-based therapies for Huntington’s disease: delivery challenges and opportunities. Ther Deliv. 2012;3:1061-1076. [PMID: 23035592 DOI: 10.4155/tde.12.80] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
41 Chen X, Mu P, Zhu L, Mao X, Chen S, Zhong H, Deng Y. T-2 Toxin Induces Oxidative Stress at Low Doses via Atf3ΔZip2a/2b-Mediated Ubiquitination and Degradation of Nrf2. Int J Mol Sci 2021;22:7936. [PMID: 34360702 DOI: 10.3390/ijms22157936] [Reference Citation Analysis]
42 Antimisiaris S, Mourtas S, Papadia K. Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential. Int J Pharm 2017;525:293-312. [PMID: 28163221 DOI: 10.1016/j.ijpharm.2017.01.056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
43 Almeida AM, Queiroz JA, Sousa F, Sousa Â. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discovery Today 2019;24:2044-57. [DOI: 10.1016/j.drudis.2019.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
44 Charbe NB, Amnerkar ND, Ramesh B, Tambuwala MM, Bakshi HA, Aljabali AAA, Khadse SC, Satheeshkumar R, Satija S, Metha M, Chellappan DK, Shrivastava G, Gupta G, Negi P, Dua K, Zacconi FC. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B 2020;10:2075-109. [PMID: 33304780 DOI: 10.1016/j.apsb.2020.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
45 Moazeni M, Khoramizadeh MR, Kordbacheh P, Sepehrizadeh Z, Zeraati H, Noorbakhsh F, Teimoori-toolabi L, Rezaie S. RNA-Mediated Gene Silencing in Candida albicans: Inhibition of Hyphae Formation by Use of RNAi Technology. Mycopathologia 2012;174:177-85. [DOI: 10.1007/s11046-012-9539-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
46 Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, Alarcón-Hernández E, Ibáñez-Hernández M. Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters. Front Oncol 2020;10:605380. [PMID: 33381459 DOI: 10.3389/fonc.2020.605380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
47 Gankhuyag N, Yu KN, Davaadamdin O, Lee S, Cho WY, Park C, Jiang HL, Singh B, Chae CH, Cho MH, Cho CS. Suppression of Tobacco Carcinogen-Induced Lung Tumorigenesis by Aerosol-Delivered Glycerol Propoxylate Triacrylate-Spermine Copolymer/Short Hairpin Rab25 RNA Complexes in Female A/J Mice. J Aerosol Med Pulm Drug Deliv 2017;30:81-90. [PMID: 27792477 DOI: 10.1089/jamp.2016.1301] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Gvozdeva OV, Prassolov VS, Zenkova MA, Vlassov VV, Chernolovskaya EL. Silencing of Inducible Immunoproteasome Subunit Expression by Chemically Modified siRNA and shRNA. Nucleosides Nucleotides Nucleic Acids 2016;35:389-403. [PMID: 27351110 DOI: 10.1080/15257770.2016.1184275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Andalib MN, Lee JS, Ha L, Dzenis Y, Lim JY. The role of RhoA kinase (ROCK) in cell alignment on nanofibers. Acta Biomaterialia 2013;9:7737-45. [DOI: 10.1016/j.actbio.2013.04.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
50 Feng Q, Zhang H, Yao D, Chen WD, Wang YD. Emerging Role of Non-Coding RNAs in Esophageal Squamous Cell Carcinoma. Int J Mol Sci. 2019;21. [PMID: 31905958 DOI: 10.3390/ijms21010258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
51 Aznan AN, Abdul Karim N, Wan Ngah WZ, Jubri Z. Critical factors for lentivirus-mediated PRDX4 gene transfer in the HepG2 cell line. Oncol Lett 2018;16:73-82. [PMID: 29930713 DOI: 10.3892/ol.2018.8650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Chuang YF, Wang PY, Kumar S, Lama S, Lin FL, Liu GS. Methods for in vitro CRISPR/CasRx-Mediated RNA Editing. Front Cell Dev Biol 2021;9:667879. [PMID: 34178991 DOI: 10.3389/fcell.2021.667879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Kwak JS, Kim KH. Generation of Self-Inhibitory Recombinant Viral Hemorrhagic Septicemia Virus (VHSV) by Insertion of Viral P Gene-Targeting Artificial MicroRNA into Viral Genome and Effect of Dicer Gene Knockout on the Recombinant VHSV Replication. Mar Biotechnol (NY) 2021. [PMID: 34268626 DOI: 10.1007/s10126-021-10045-4] [Reference Citation Analysis]
54 Tsanov M. Neurons under genetic control: What are the next steps towards the treatment of movement disorders? Comput Struct Biotechnol J 2020;18:3577-89. [PMID: 33304456 DOI: 10.1016/j.csbj.2020.11.012] [Reference Citation Analysis]
55 Kumar V, Mahato RI. Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res 2015;32:341-61. [PMID: 25186440 DOI: 10.1007/s11095-014-1497-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
56 Andrews L, Ralston S, Blomme E, Barnhart K. A snapshot of biologic drug development: Challenges and opportunities. Hum Exp Toxicol 2015;34:1279-85. [DOI: 10.1177/0960327115603594] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
57 Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128-141. [PMID: 24859533 DOI: 10.1016/j.addr.2014.05.009] [Cited by in Crossref: 352] [Cited by in F6Publishing: 314] [Article Influence: 50.3] [Reference Citation Analysis]
58 Lama L, Seidl CI, Ryan K. New insights into the promoterless transcription of DNA coligo templates by RNA polymerase III. Transcription 2014;5:e27913. [PMID: 25764216 DOI: 10.4161/trns.27913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
59 Zheng D, Hou Y, Li Y, Bian Y, Khan M, Li F, Huang L, Qiao C. Long Non-coding RNA Gas5 Is Associated With Preeclampsia and Regulates Biological Behaviors of Trophoblast via MicroRNA-21. Front Genet 2020;11:188. [PMID: 32194641 DOI: 10.3389/fgene.2020.00188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
60 Pawlowska R, Gwozdzinska P, Chworos A. RNA Nanoparticles for Gene Expression Regulation. In: Erdmann VA, Barciszewski J, editors. DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases. Berlin: Springer Berlin Heidelberg; 2013. pp. 263-90. [DOI: 10.1007/978-3-662-45775-7_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Qiu Y, Lam JK, Leung SW, Liang W. Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside. Molecules 2016;21:E1249. [PMID: 27657028 DOI: 10.3390/molecules21091249] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
62 Álvarez-Rodríguez B, Latorre A, Posch C, Somoza Á. Recent advances in uveal melanoma treatment. Med Res Rev 2017;37:1350-72. [PMID: 28759124 DOI: 10.1002/med.21460] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
63 Han L, Tang C, Yin C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials. 2014;35:4589-4600. [PMID: 24613049 DOI: 10.1016/j.biomaterials.2014.02.027] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
64 Laufer SD, Detzer A, Sczakiel G, Restle T. Selected Strategies for the Delivery of siRNA In Vitro and In Vivo. In: Erdmann VA, Barciszewski J, editors. RNA Technologies and Their Applications. Berlin: Springer Berlin Heidelberg; 2010. pp. 29-58. [DOI: 10.1007/978-3-642-12168-5_2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
65 Kobayashi M, Huang CL, Sonobe M, Kikuchi R, Ishikawa M, Kitamura J, Miyahara R, Menju T, Iwakiri S, Itoi K, Yasumizu R, Date H. Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients. Exp Ther Med 2012;3:952-8. [PMID: 22969998 DOI: 10.3892/etm.2012.511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
66 Coelho JF, Ferreira PC, Alves P, Cordeiro R, Fonseca AC, Góis JR, Gil MH. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J 2010;1:164-209. [PMID: 23199049 DOI: 10.1007/s13167-010-0001-x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 110] [Article Influence: 15.9] [Reference Citation Analysis]
67 Du GM, Wu JG, Luo BP, Hu ZH, Li LA, Liu MJ. RNAi-mediated Ghrelin affects gastric H(+)-K(+)-ATPase activity and expression of GOAT-Ghrelin system in vitro. Gen Comp Endocrinol 2016;228:48-52. [PMID: 26873629 DOI: 10.1016/j.ygcen.2016.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
68 Clark ZJ, Miranpuri GS, Resnick DK. In Vivo application of RNAi to study pain. Ann Neurosci 2010;17:142-5. [PMID: 25205892 DOI: 10.5214/ans.0972-7531.1017310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
69 Jiang Q, Dai L, Cheng L, Chen X, Li Y, Zhang S, Su X, Zhao X, Wei Y, Deng H. Efficient inhibition of intraperitoneal ovarian cancer growth in nude mice by liposomal delivery of short hairpin RNA against STAT3. J Obstet Gynaecol Res 2013;39:701-9. [PMID: 23003327 DOI: 10.1111/j.1447-0756.2012.02007.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
70 Wu S, Tang S, Peng H, Jiang Y, Liu Y, Wu Z, Liu Q, Zhu X. Effects of lentivirus-mediated CCR3 RNA interference on the function of mast cells of allergic rhinitis in mice. International Immunopharmacology 2020;78:106011. [DOI: 10.1016/j.intimp.2019.106011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Tai W. Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery. Molecules 2019;24:E2211. [PMID: 31200490 DOI: 10.3390/molecules24122211] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
72 Torrecilla J, del Pozo-Rodríguez A, Apaolaza PS, Solinís MÁ, Rodríguez-Gascón A. Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. Int J Pharm 2015;479:181-8. [PMID: 25542984 DOI: 10.1016/j.ijpharm.2014.12.047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
73 Park SK, Kee Y, Ryu T, Kim H, Hwang BJ. Enzymatic construction of shRNA library from oligonucleotide library. Genes Genomics 2019;41:573-81. [PMID: 30830681 DOI: 10.1007/s13258-019-00800-2] [Reference Citation Analysis]
74 Ramos J, Rege K. Poly(aminoether)-gold nanorod assemblies for shRNA plasmid-induced gene silencing. Mol Pharm 2013;10:4107-19. [PMID: 24066795 DOI: 10.1021/mp400080f] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
75 Lin G, Revia RA, Zhang M. Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities. Adv Funct Mater 2021;31:2007096. [PMID: 34366761 DOI: 10.1002/adfm.202007096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Hu Z, Zhang H, Haley B, Macchi F, Yang F, Misaghi S, Elich J, Yang R, Tang Y, Joly JC, Snedecor BR, Shen A. Carboxypeptidase D is the only enzyme responsible for antibody C-terminal lysine cleavage in Chinese hamster ovary (CHO) cells: Chinese Hamster Ovary Cells. Biotechnol Bioeng 2016;113:2100-6. [DOI: 10.1002/bit.25977] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
77 Ovalle-bracho C, Londoño-barbosa DA, Franco-muñoz C, Clavijo-ramírez C. Functional evaluation of gene silencing on macrophages derived from U937 cells using interference RNA (shRNA) in a model of macrophages infected with Leishmania ( Viannia ) braziliensis. Parasitology 2015;142:1682-92. [DOI: 10.1017/s0031182015001304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Ayatollahi S, Salmasi Z, Hashemi M, Askarian S, Oskuee RK, Abnous K, Ramezani M. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. Int J Biochem Cell Biol 2017;92:210-7. [PMID: 29031805 DOI: 10.1016/j.biocel.2017.10.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
79 Glombik M, Bačovský V, Hobza R, Kopecký D. Competition of Parental Genomes in Plant Hybrids. Front Plant Sci 2020;11:200. [PMID: 32158461 DOI: 10.3389/fpls.2020.00200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
80 Coussens MJ, Corman C, Fischer AL, Sago J, Swarthout J. MISSION LentiPlex pooled shRNA library screening in mammalian cells. J Vis Exp 2011:3305. [PMID: 22215108 DOI: 10.3791/3305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
81 Jin G, Palecek SP. Inductive factors for generation of pluripotent stem cell-derived cardiomyocytes. Engineering Strategies for Regenerative Medicine. Elsevier; 2020. pp. 177-242. [DOI: 10.1016/b978-0-12-816221-7.00006-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Şalva E, Kabasakal L, Eren F, Çakalağaoğlu F, Özkan N, Akbuğa J. Chitosan/Short Hairpin RNA Complexes for Vascular Endothelial Growth Factor Suppression Invasive Breast Carcinoma. Oligonucleotides 2010;20:183-90. [DOI: 10.1089/oli.2010.0241] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
83 O’Hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, Pontén F, Gallagher WM, Lindskog C. Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol. 2014;8:783-798. [PMID: 24725481 DOI: 10.1016/j.molonc.2014.03.008] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
84 Campbell M, Ozaki E, Humphries P. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Expert Opinion on Drug Delivery 2010;7:859-69. [DOI: 10.1517/17425247.2010.490554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
85 Liu SH, Rao DD, Nemunaitis J, Senzer N, Zhou G, Dawson D, Gingras MC, Wang Z, Gibbs R, Norman M, Templeton NS, Demayo FJ, O'Malley B, Sanchez R, Fisher WE, Brunicardi FC. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One 2012;7:e40452. [PMID: 22905092 DOI: 10.1371/journal.pone.0040452] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
86 Yao J, Da M, Guo T, Duan Y, Zhang Y. RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice. Tumor Biol 2013;34:1493-501. [DOI: 10.1007/s13277-013-0674-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
87 Andalib MN, Lee JS, Ha L, Dzenis Y, Lim JY. Focal adhesion kinase regulation in stem cell alignment and spreading on nanofibers. Biochem Biophys Res Commun 2016;473:920-5. [PMID: 27040763 DOI: 10.1016/j.bbrc.2016.03.151] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
88 Bharadwaj U, Kasembeli MM, Tweardy DJ. STAT3 Inhibitors in Cancer: A Comprehensive Update. In: Ward AC, editor. STAT Inhibitors in Cancer. Cham: Springer International Publishing; 2016. pp. 95-161. [DOI: 10.1007/978-3-319-42949-6_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
89 Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013;65:1784-802. [PMID: 23880506 DOI: 10.1016/j.addr.2013.07.012] [Cited by in Crossref: 195] [Cited by in F6Publishing: 167] [Article Influence: 24.4] [Reference Citation Analysis]
90 Malhotra M, Toulouse A, Godinho BM, Mc Carthy DJ, Cryan JF, O'Driscoll CM. RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies. Mol Biosyst 2015;11:2635-57. [PMID: 26135606 DOI: 10.1039/c5mb00278h] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
91 Liao YJ, Chen YS, Lee JX, Chen LR, Yang JR. Effects of Klf4 and c-Myc Knockdown on Pluripotency Maintenance in Porcine Induced Pluripotent Stem Cell. Cell J 2018;19:640-6. [PMID: 29105400 DOI: 10.22074/cellj.2018.4428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Allison SJ, Milner J. RNA Interference by Single- and Double-stranded siRNA With a DNA Extension Containing a 3' Nuclease-resistant Mini-hairpin Structure. Mol Ther Nucleic Acids 2014;2:e141. [PMID: 24399205 DOI: 10.1038/mtna.2013.68] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
93 Blenn C, Wyrsch P, Althaus FR. The Sound of Silence: RNAi in Poly (ADP-Ribose) Research. Genes (Basel) 2012;3:779-805. [PMID: 24705085 DOI: 10.3390/genes3040779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Buijsen RAM, Toonen LJA, Gardiner SL, van Roon-Mom WMC. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. Neurotherapeutics 2019;16:263-86. [PMID: 30607747 DOI: 10.1007/s13311-018-00696-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 43.0] [Reference Citation Analysis]
95 Iyer AK, Duan Z, Amiji MM. Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors. Mol Pharmaceutics 2014;11:2511-26. [DOI: 10.1021/mp500024p] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
96 Asgarpour K, Shojaei Z, Amiri F, Ai J, Mahjoubin-Tehran M, Ghasemi F, ArefNezhad R, Hamblin MR, Mirzaei H. Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun Signal 2020;18:149. [PMID: 32917227 DOI: 10.1186/s12964-020-00650-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
97 Malavia N, Kuche K, Ghadi R, Jain S. A bird's eye view of the advanced approaches and strategies for overshadowing triple negative breast cancer. J Control Release 2021;330:72-100. [PMID: 33321156 DOI: 10.1016/j.jconrel.2020.12.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
98 Jollé C, Déglon N, Pythoud C, Bouzier-Sore AK, Pellerin L. Development of Efficient AAV2/DJ-Based Viral Vectors to Selectively Downregulate the Expression of Neuronal or Astrocytic Target Proteins in the Rat Central Nervous System. Front Mol Neurosci 2019;12:201. [PMID: 31481874 DOI: 10.3389/fnmol.2019.00201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
99 Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19:937-954. [PMID: 22921062 DOI: 10.1016/j.chembiol.2012.07.011] [Cited by in Crossref: 391] [Cited by in F6Publishing: 339] [Article Influence: 43.4] [Reference Citation Analysis]
100 Chen S, Feng J, Ma L, Liu Z, Yuan W. RNA interference technology for anti-VEGF treatment. Expert Opinion on Drug Delivery 2014;11:1471-80. [DOI: 10.1517/17425247.2014.926886] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
101 Paris JL, Vallet-Regí M. Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review. Pharmaceutics 2020;12:E526. [PMID: 32521800 DOI: 10.3390/pharmaceutics12060526] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
102 Taiarol L, Formicola B, Magro RD, Sesana S, Re F. An update of nanoparticle-based approaches for glioblastoma multiforme immunotherapy. Nanomedicine (Lond) 2020;15:1861-71. [PMID: 32731839 DOI: 10.2217/nnm-2020-0132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
103 Gao K, Huang L. Achieving efficient RNAi therapy: progress and challenges. Acta Pharmaceutica Sinica B 2013;3:213-25. [DOI: 10.1016/j.apsb.2013.06.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
104 del Pozo-rodríguez A, Solinís MÁ, Rodríguez-gascón A. Applications of lipid nanoparticles in gene therapy. European Journal of Pharmaceutics and Biopharmaceutics 2016;109:184-93. [DOI: 10.1016/j.ejpb.2016.10.016] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 8.6] [Reference Citation Analysis]
105 Javan B, Shahbazi M. Constructing a Novel Hypoxia-Inducible Bidirectional shRNA Expression Vector for Simultaneous Gene Silencing in Colorectal Cancer Gene Therapy. Cancer Biother Radiopharm 2018;33:118-23. [PMID: 29641253 DOI: 10.1089/cbr.2017.2401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Baudet S, Bécret J, Nicol X. Approaches to Manipulate Ephrin-A:EphA Forward Signaling Pathway. Pharmaceuticals (Basel) 2020;13:E140. [PMID: 32629797 DOI: 10.3390/ph13070140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
107 Berto S, Usui N, Konopka G, Fogel BL. ELAVL2-regulated transcriptional and splicing networks in human neurons link neurodevelopment and autism. Hum Mol Genet 2016;25:2451-64. [PMID: 27260404 DOI: 10.1093/hmg/ddw110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
108 Choi SH, Kwon OJ, Park JY, Kim DY, Ahn SH, Kim SU, Ro SW, Kim KS, Park JH, Kim S, Yun CO, Han KH. Inhibition of tumour angiogenesis and growth by small hairpin HIF-1α and IL-8 in hepatocellular carcinoma. Liver Int 2014;34:632-42. [PMID: 24321089 DOI: 10.1111/liv.12375] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
109 Li Y, Feng H, Jin L, Xin X, Yuan Q. A novel vector-based RNAi method using mouse U6 promoter-driven shRNA expression in the filamentous fungus Blakeslea trispora. Biotechnol Lett 2021;43:1821-30. [PMID: 34185215 DOI: 10.1007/s10529-021-03155-5] [Reference Citation Analysis]
110 Mokhtarzadeh A, Parhiz H, Hashemi M, Abnous K, Ramezani M. P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells. Expert Opinion on Drug Delivery 2016;13:477-91. [DOI: 10.1517/17425247.2016.1126245] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
111 Zeng L, Li D, Tong W, Shi T, Ning B. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. Biochem Pharmacol 2021;189:114424. [PMID: 33482149 DOI: 10.1016/j.bcp.2021.114424] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
112 Chen ZY, Liang K, Lin Y, Yang F. Study of the UTMD-based delivery system to induce cervical cancer cell apoptosis and inhibit proliferation with shRNA targeting Survivin. Int J Mol Sci 2013;14:1763-77. [PMID: 23325045 DOI: 10.3390/ijms14011763] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
113 Chen YG, Mathews CE, Driver JP. The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future. Front Endocrinol (Lausanne) 2018;9:51. [PMID: 29527189 DOI: 10.3389/fendo.2018.00051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
114 Zhang Y, Yan L, Zhao Y, Ou L, Wu X, Luo C. Knockdown of phospholipase C-epsilon by short-hairpin RNA-mediated gene silencing induces apoptosis in human bladder cancer cell lines. Cancer Biother Radiopharm 2013;28:233-9. [PMID: 23484808 DOI: 10.1089/cbr.2012.1216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
115 Lin SY, Lin FS, Chen MK, Tsai LR, Jao YC, Lin HY, Wang CL, Hwu YK, Yang CS. One-pot synthesis of linear-like and photoluminescent polyethylenimines for intracellular imaging and siRNA delivery. Chem Commun (Camb) 2010;46:5554-6. [PMID: 20505856 DOI: 10.1039/c002775h] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
116 Touchefeu Y, Harrington KJ, Galmiche JP, Vassaux G. Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. Aliment Pharmacol Ther. 2010;32:953-968. [PMID: 20937041 DOI: 10.1111/j.1365-2036.2010.04424.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
117 Chen L, Yuan D, Zhao R, Li H, Zhu J. Suppression of TSPAN1 by RNA Interference Inhibits Proliferation and Invasion of Colon Cancer Cells in Vitro. Tumori 2010;96:744-50. [DOI: 10.1177/030089161009600517] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
118 Chowdhury N, Vhora I, Patel K, Doddapaneni R, Mondal A, Singh M. Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer. Pharm Res 2017;34:2371-84. [PMID: 28875330 DOI: 10.1007/s11095-017-2244-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
119 Bortolozzi A, Manashirov S, Chen A, Artigas F. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. Pharmacol Ther 2021;227:107873. [PMID: 33915178 DOI: 10.1016/j.pharmthera.2021.107873] [Reference Citation Analysis]
120 Bownes LV, Williams AP, Marayati R, Quinn CH, Hutchins SC, Stewart JE, Vu T, Easlick JL, Mroczek-Musulman E, Crossman DK, Anderson JC, Willey CD, Datta PK, Beierle EA. Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines. Cancers (Basel) 2021;13:3201. [PMID: 34206917 DOI: 10.3390/cancers13133201] [Reference Citation Analysis]
121 Cohen JL, Schubert S, Wich PR, Cui L, Cohen JA, Mynar JL, Fréchet JM. Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug Chem 2011;22:1056-65. [PMID: 21539393 DOI: 10.1021/bc100542r] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 10.8] [Reference Citation Analysis]
122 Weinstein S, Emmanuel R, Jacobi AM, Abraham A, Behlke MA, Sprague AG, Novobrantseva TI, Nagler A, Peer D. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. PLoS One 2012;7:e43343. [PMID: 22905260 DOI: 10.1371/journal.pone.0043343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
123 Shaabani E, Sharifiaghdam M, De Keersmaecker H, De Rycke R, De Smedt S, Faridi-Majidi R, Braeckmans K, Fraire JC. Layer by Layer Assembled Chitosan-Coated Gold Nanoparticles for Enhanced siRNA Delivery and Silencing. Int J Mol Sci 2021;22:E831. [PMID: 33467656 DOI: 10.3390/ijms22020831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
124 Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011;300:10-19. [PMID: 20965651 DOI: 10.1016/j.canlet.2010.09.019] [Cited by in Crossref: 126] [Cited by in F6Publishing: 115] [Article Influence: 11.5] [Reference Citation Analysis]
125 O'Donnell JM, Kalichira A, Bi J, Lewandowski ED. In vivo, cardiac-specific knockdown of a target protein, malic enzyme-1, in rat via adenoviral delivery of DNA for non-native miRNA. Curr Gene Ther 2012;12:454-62. [PMID: 22974418 DOI: 10.2174/156652312803519760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
126 Chen Z, Zhang L, He Y, Shen Y, Li Y. Enhanced shRNA delivery and ABCG2 silencing by charge-reversible layered nanocarriers. Small 2015;11:952-62. [PMID: 25330768 DOI: 10.1002/smll.201401397] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
127 Cini M, Bradshaw TD, Woodward S. Using titanium complexes to defeat cancer: the view from the shoulders of titans. Chem Soc Rev 2017;46:1040-51. [DOI: 10.1039/c6cs00860g] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 14.8] [Reference Citation Analysis]
128 Dong Q, Zhang H, Han Y, Djamila A, Cheng H, Tang Z, Zhou J, Ding Y. Tumor environment differentiated “nanodepot” programmed for site-specific drug shuttling and combinative therapy on metastatic cancer. Journal of Controlled Release 2018;283:59-75. [DOI: 10.1016/j.jconrel.2018.05.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
129 Chen YR, Feng WY, Cheng YX, Zhu H, Liu HJ, Gao Y, Zhou WJ. siRNAs Targeting Mouse-Specific lncRNA AA388235 Induce Human Tumor Cell Pyroptosis/Apoptosis. Front Oncol 2021;11:662444. [PMID: 34195074 DOI: 10.3389/fonc.2021.662444] [Reference Citation Analysis]
130 Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. Pancreatic cancer actionable genes in precision medicine and personalized surgery. Surgeon 2017;15:24-9. [PMID: 27374183 DOI: 10.1016/j.surge.2016.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
131 Kreidberg JA. siRNA Therapy for Glomerulonephritis. JASN 2010;21:549-51. [DOI: 10.1681/asn.2010020177] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Teymournejad O, Rikihisa Y. Ehrlichia chaffeensis Uses an Invasin To Suppress Reactive Oxygen Species Generation by Macrophages via CD147-Dependent Inhibition of Vav1 To Block Rac1 Activation. mBio 2020;11:e00267-20. [PMID: 32317318 DOI: 10.1128/mBio.00267-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
133 Fariya M, Jain A, Dhawan V, Shah S, Nagarsenker MS. Bolaamphiphiles: a pharmaceutical review. Adv Pharm Bull 2014;4:483-91. [PMID: 25671179 DOI: 10.5681/apb.2014.072] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
134 Maguregui A, Abe H. Developments in siRNA Modification and Ligand Conjugated Delivery To Enhance RNA Interference Ability. Chembiochem 2020;21:1808-15. [PMID: 32181563 DOI: 10.1002/cbic.202000009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
135 Aguiar S, van der Gaag B, Cortese FAB. RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. Transl Neurodegener 2017;6:30. [PMID: 29209494 DOI: 10.1186/s40035-017-0101-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
136 Mansoori B, Sandoghchian Shotorbani S, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull 2014;4:313-21. [PMID: 25436185 DOI: 10.5681/apb.2014.046] [Cited by in F6Publishing: 53] [Reference Citation Analysis]
137 Tokunaga Y, Liu D, Nakano J, Zhang X, Nii K, Go T, Huang CL, Yokomise H. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells. Eur J Cancer 2015;51:2480-9. [PMID: 26254808 DOI: 10.1016/j.ejca.2015.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
138 Chen J, Lu L, feng Y, Wang H, Dai L, li Y, Zhang P. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Letters 2011;300:48-56. [DOI: 10.1016/j.canlet.2010.09.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
139 Willebrords J, Maes M, Crespo Yanguas S, Vinken M. Inhibitors of connexin and pannexin channels as potential therapeutics. Pharmacol Ther 2017;180:144-60. [PMID: 28720428 DOI: 10.1016/j.pharmthera.2017.07.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 19.8] [Reference Citation Analysis]
140 Ahlemeyer B, Vogt JF, Michel V, Hahn-Kohlberger P, Baumgart-Vogt E. Microporation is an efficient method for siRNA-induced knockdown of PEX5 in HepG2 cells: evaluation of the transfection efficiency, the PEX5 mRNA and protein levels and induction of peroxisomal deficiency. Histochem Cell Biol 2014;142:577-91. [PMID: 25224142 DOI: 10.1007/s00418-014-1254-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
141 Li F, Mahato RI. RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev 2011;63:47-68. [PMID: 21156190 DOI: 10.1016/j.addr.2010.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
142 Savarin M, Kamensek U, Znidar K, Todorovic V, Sersa G, Cemazar M. Evaluation of a Novel Plasmid for Simultaneous Gene Electrotransfer-Mediated Silencing of CD105 and CD146 in Combination with Irradiation. Int J Mol Sci 2021;22:3069. [PMID: 33802812 DOI: 10.3390/ijms22063069] [Reference Citation Analysis]
143 Taylor J, Woodcock S. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way? J Biomol Screen 2015;20:1040-51. [PMID: 26048892 DOI: 10.1177/1087057115590069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
144 Kühling L, Schelhaas M. Systematic analysis of endocytosis by cellular perturbations. Methods Mol Biol 2014;1174:19-46. [PMID: 24947372 DOI: 10.1007/978-1-4939-0944-5_2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
145 Lee AJ, Swanton C. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochem Pharmacol. 2012;83:1013-1020. [PMID: 22192819 DOI: 10.1016/j.bcp.2011.12.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
146 Zhang C, Wang Y, Wu H, Zhang Z, Cai Y, Hou H, Zhao W, Yang X, Ma J. Inhibitory efficacy of hypoxia-inducible factor 1α short hairpin RNA plasmid DNA-loaded poly (D, L-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model. Gene Ther 2010;17:338-51. [DOI: 10.1038/gt.2009.158] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
147 Swami R, Kumar Y, Chaudhari D, Katiyar SS, Kuche K, Katare PB, Banerjee SK, Jain S. pH sensitive liposomes assisted specific and improved breast cancer therapy using co-delivery of SIRT1 shRNA and Docetaxel. Materials Science and Engineering: C 2021;120:111664. [DOI: 10.1016/j.msec.2020.111664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
148 Walton SP, Wu M, Gredell JA, Chan C. Designing highly active siRNAs for therapeutic applications. FEBS J 2010;277:4806-13. [PMID: 21078115 DOI: 10.1111/j.1742-4658.2010.07903.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
149 Ma LS, Yan QI, Huang Y, Zhao W, Zhu YU. Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells. Oncol Lett 2015;9:2211-7. [PMID: 26137043 DOI: 10.3892/ol.2015.3033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Labatut AE, Mattheolabakis G. Non-viral based miR delivery and recent developments. Eur J Pharm Biopharm 2018;128:82-90. [PMID: 29679644 DOI: 10.1016/j.ejpb.2018.04.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
151 Vauthier C, Zandanel C, Ramon AL. Chitosan-based nanoparticles for in vivo delivery of interfering agents including siRNA. Current Opinion in Colloid & Interface Science 2013;18:406-18. [DOI: 10.1016/j.cocis.2013.06.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 5.1] [Reference Citation Analysis]
152 Arima H, Motoyama K. Recent Findings Concerning PAMAM Dendrimer Conjugates with Cyclodextrins as Carriers of DNA and RNA. Sensors (Basel) 2009;9:6346-61. [PMID: 22454589 DOI: 10.3390/s90806346] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
153 Yang L, Tian Y, Leong WS, Song H, Yang W, Wang M, Wang X, Kong J, Shan B, Song Z. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro. Breast Cancer Res 2018;20:113. [PMID: 30227879 DOI: 10.1186/s13058-018-1042-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
154 Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol 2013;6:90. [PMID: 24308725 DOI: 10.1186/1756-8722-6-90] [Cited by in Crossref: 116] [Cited by in F6Publishing: 106] [Article Influence: 14.5] [Reference Citation Analysis]
155 Seidl CI, Lama L, Ryan K. Circularized synthetic oligodeoxynucleotides serve as promoterless RNA polymerase III templates for small RNA generation in human cells. Nucleic Acids Res 2013;41:2552-64. [PMID: 23275570 DOI: 10.1093/nar/gks1334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
156 Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013;31:1397-407. [PMID: 23800690 DOI: 10.1016/j.biotechadv.2013.06.004] [Cited by in Crossref: 147] [Cited by in F6Publishing: 124] [Article Influence: 18.4] [Reference Citation Analysis]
157 Ma R, Liu Q, Zheng S, Liu T, Tan D, Lu X. PKM2-regulated STAT3 promotes esophageal squamous cell carcinoma progression via TGF-β1-induced EMT. J Cell Biochem 2019. [PMID: 30756445 DOI: 10.1002/jcb.28434] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
158 Zhao G, Huang Q, Wang F, Zhang X, Hu J, Tan Y, Huang N, Wang Z, Wang Z, Cheng Y. Targeted shRNA-loaded liposome complex combined with focused ultrasound for blood brain barrier disruption and suppressing glioma growth. Cancer Letters 2018;418:147-58. [DOI: 10.1016/j.canlet.2018.01.035] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
159 Morla-folch J, Xie H, Alvarez-puebla RA, Guerrini L. Fast Optical Chemical and Structural Classification of RNA. ACS Nano 2016;10:2834-42. [DOI: 10.1021/acsnano.5b07966] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
160 Yu SQ, Wang DH. Intrathecal injection of TRPV1 shRNA leads to increases in blood pressure in rats. Acta Physiol (Oxf) 2011;203:139-47. [PMID: 21518266 DOI: 10.1111/j.1748-1716.2011.02285.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
161 Fernandez-piñeiro I, Badiola I, Sanchez A. Nanocarriers for microRNA delivery in cancer medicine. Biotechnology Advances 2017;35:350-60. [DOI: 10.1016/j.biotechadv.2017.03.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
162 Lew-tabor A, Kurscheid S, Barrero R, Gondro C, Moolhuijzen P, Rodriguez Valle M, Morgan J, Covacin C, Bellgard M. Gene expression evidence for off-target effects caused by RNA interference-mediated gene silencing of Ubiquitin-63E in the cattle tick Rhipicephalus microplus. International Journal for Parasitology 2011;41:1001-14. [DOI: 10.1016/j.ijpara.2011.05.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
163 Bayona-Bafaluy MP, Sánchez-Cabo F, Fernández-Silva P, Pérez-Martos A, Enríquez JA. A genome-wide shRNA screen for new OxPhos related genes. Mitochondrion 2011;11:467-75. [PMID: 21292037 DOI: 10.1016/j.mito.2011.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
164 Singh P, Singh A, Shah S, Vataliya J, Mittal A, Chitkara D. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme. Mol Pharm 2020;17:4040-66. [PMID: 32902291 DOI: 10.1021/acs.molpharmaceut.0c00709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
165 Wong GT, Chang RC, Law AC. A breach in the scaffold: the possible role of cytoskeleton dysfunction in the pathogenesis of major depression. Ageing Res Rev 2013;12:67-75. [PMID: 22995339 DOI: 10.1016/j.arr.2012.08.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
166 Islam SMS, Sohn S. HSV-Induced Systemic Inflammation as an Animal Model for Behçet's Disease and Therapeutic Applications. Viruses 2018;10:E511. [PMID: 30235840 DOI: 10.3390/v10090511] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
167 Li X, Zhou X, Liu Y, Fan J, Huo H, Yao J, Wang L, Ma N. Overexpression of monocarboxylate transporter 4 promotes the migration and invasion of non-carcinogenic L929 fibroblast cells. Oncol Lett 2021;21:44. [PMID: 33262836 DOI: 10.3892/ol.2020.12305] [Reference Citation Analysis]
168 Ghatak S, Hascall VC, Markwald RR, Feghali-Bostwick C, Artlett CM, Gooz M, Bogatkevich GS, Atanelishvili I, Silver RM, Wood J, Thannickal VJ, Misra S. Transforming growth factor β1 (TGFβ1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. J Biol Chem 2017;292:10490-519. [PMID: 28389561 DOI: 10.1074/jbc.M116.752469] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 11.8] [Reference Citation Analysis]
169 Wirth M, Fritsche P, Stojanovic N, Brandl M, Jaeckel S, Schmid RM, Saur D, Schneider G. A simple and cost-effective method to transfect small interfering RNAs into pancreatic cancer cell lines using polyethylenimine. Pancreas 2011;40:144-50. [PMID: 20938367 DOI: 10.1097/MPA.0b013e3181f7e41c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
170 Lee MY, Park YH. Potential of Gene and Cell Therapy for Inner Ear Hair Cells. Biomed Res Int. 2018;2018:8137614. [PMID: 30009175 DOI: 10.1155/2018/8137614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
171 Aghamiri S, Mehrjardi KF, Shabani S, Keshavarz-Fathi M, Kargar S, Rezaei N. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy? Nanomedicine (Lond) 2019;14:2083-100. [PMID: 31368405 DOI: 10.2217/nnm-2018-0379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
172 Boese AS, Majer A, Saba R, Booth SA. Small RNA drugs for prion disease: a new frontier. Expert Opinion on Drug Discovery 2013;8:1265-84. [DOI: 10.1517/17460441.2013.818976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
173 Kwon YJ. Before and after endosomal escape: roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency. Acc Chem Res 2012;45:1077-88. [PMID: 22103667 DOI: 10.1021/ar200241v] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 8.5] [Reference Citation Analysis]
174 Tsvetkov L, Nanjundan M, Domino M, Daniel KG. The ubiquitin–proteasome system and assays to determine responses to inhibitors. Expert Opinion on Drug Discovery 2010;5:1221-36. [DOI: 10.1517/17460441.2010.530654] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
175 Dvorská D, Braný D, Ňachajová M, Halašová E, Danková Z. Breast Cancer and the Other Non-Coding RNAs. Int J Mol Sci 2021;22:3280. [PMID: 33807045 DOI: 10.3390/ijms22063280] [Reference Citation Analysis]
176 Khandelia P, Yap K, Makeyev EV. Streamlined platform for short hairpin RNA interference and transgenesis in cultured mammalian cells. Proc Natl Acad Sci U S A 2011;108:12799-804. [PMID: 21768390 DOI: 10.1073/pnas.1103532108] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
177 Obeidy P, Ju LA, Oehlers SH, Zulkhernain NS, Lee Q, Galeano Niño JL, Kwan RY, Tikoo S, Cavanagh LL, Mrass P, Cook AJ, Jackson SP, Biro M, Roediger B, Sixt M, Weninger W. Partial loss of actin nucleator actin-related protein 2/3 activity triggers blebbing in primary T lymphocytes. Immunol Cell Biol 2020;98:93-113. [PMID: 31698518 DOI: 10.1111/imcb.12304] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
178 Kilcher S, Mercer J. Next generation approaches to study virus entry and infection. Current Opinion in Virology 2014;4:8-14. [DOI: 10.1016/j.coviro.2013.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
179 Konopnicki CM, Dickmann LJ, Tracy JM, Tukey RH, Wienkers LC, Foti RS. Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes. Arch Biochem Biophys 2013;535:143-9. [PMID: 23562620 DOI: 10.1016/j.abb.2013.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
180 Panda D, Cherry S. Cell-based genomic screening: elucidating virus-host interactions. Curr Opin Virol. 2012;2:784-792. [PMID: 23122855 DOI: 10.1016/j.coviro.2012.10.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
181 Callaghan NI, Hadipour-Lakmehsari S, Lee SH, Gramolini AO, Simmons CA. Modeling cardiac complexity: Advancements in myocardial models and analytical techniques for physiological investigation and therapeutic development in vitro. APL Bioeng 2019;3:011501. [PMID: 31069331 DOI: 10.1063/1.5055873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
182 Zhang D, Zhao W, Liu J, Ou M, Liang P, Li J, Chen Y, Liao D, Bai S, Shen J, Chen X, Huang H, Zhou C. Sodium leak channel contributes to neuronal sensitization in neuropathic pain. Prog Neurobiol 2021;202:102041. [PMID: 33766679 DOI: 10.1016/j.pneurobio.2021.102041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H, Palmer A, Perkins H, Savic B, Scott S, Smith-Burchnell C. In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy. Antimicrob Agents Chemother. 2012;56:1364-1375. [PMID: 22203606 DOI: 10.1128/aac.05357-11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
184 Liu SH, Rao DD, Nemunaitis J, Senzer N, Zhou G, Dawson D, Gingras MC, Wang Z, Gibbs R, Norman M. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One. 2012;7:e40452. [PMID: 22905092 DOI: 10.1371/journal.pone.004045] [Reference Citation Analysis]
185 Liu D, Kadota K, Ueno M, Nakashima N, Yokomise H, Huang CL. Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours. Eur J Cancer 2012;48:1208-18. [PMID: 21646015 DOI: 10.1016/j.ejca.2011.05.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
186 Ando H, Saito-Tarashima N, Lila ASA, Kinjo N, Shimizu T, Ishima Y, Minakawa N, Ishida T. A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma. Molecules 2020;25:E1725. [PMID: 32283709 DOI: 10.3390/molecules25071725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
187 Salguero-Aranda C, Sancho-Mensat D, Canals-Lorente B, Sultan S, Reginald A, Chapman L. STAT6 knockdown using multiple siRNA sequences inhibits proliferation and induces apoptosis of human colorectal and breast cancer cell lines. PLoS One 2019;14:e0207558. [PMID: 31075146 DOI: 10.1371/journal.pone.0207558] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
188 Khanday MA, Somarajan BI, Mehta R, Mallick BN. Noradrenaline from Locus Coeruleus Neurons Acts on Pedunculo-Pontine Neurons to Prevent REM Sleep and Induces Its Loss-Associated Effects in Rats. eNeuro 2016;3:ENEURO. [PMID: 27957531 DOI: 10.1523/ENEURO.0108-16.2016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
189 Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 2012;20:679-86. [PMID: 22186789 DOI: 10.1038/mt.2011.269] [Cited by in Crossref: 109] [Cited by in F6Publishing: 83] [Article Influence: 10.9] [Reference Citation Analysis]
190 Baliga UK, Dean DA. Pulmonary gene delivery-Realities and possibilities. Exp Biol Med (Maywood) 2021;246:260-74. [PMID: 33183069 DOI: 10.1177/1535370220965985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Johnston SJ, Carroll JS. Transcription factors and chromatin proteins as therapeutic targets in cancer. Biochim Biophys Acta 2015;1855:183-92. [PMID: 25721328 DOI: 10.1016/j.bbcan.2015.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
192 Islam SMS, Byun HO, Choi B, Sohn S. Inhibition of CD83 Alleviates Systemic Inflammation in Herpes Simplex Virus Type 1-Induced Behçet's Disease Model Mouse. Mediators Inflamm 2019;2019:5761392. [PMID: 31582900 DOI: 10.1155/2019/5761392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
193 Gajzer DC, Balbin J, Chaudhry HW. Thymosin β4 and Cardiac Regeneration: Are We Missing a Beat? Stem Cell Rev and Rep 2013;9:303-12. [DOI: 10.1007/s12015-012-9378-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
194 de la Fuente M, Jones MC, Santander-Ortega MJ, Mirenska A, Marimuthu P, Uchegbu I, Schätzlein A. A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer. Nanomedicine 2015;11:369-77. [PMID: 25267700 DOI: 10.1016/j.nano.2014.09.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
195 Pham TP, Kremer V, Boon RA. RNA-based therapeutics in cardiovascular disease. Curr Opin Cardiol 2020;35:191-8. [PMID: 32068614 DOI: 10.1097/HCO.0000000000000724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
196 Li D, Mastaglia FL, Fletcher S, Wilton SD. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Med Res Rev 2020;40:2650-81. [PMID: 32767426 DOI: 10.1002/med.21718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
197 Tsitsipatis D, Gorospe M. Practical guide for circular RNA analysis: Steps, tips, and resources. Wiley Interdiscip Rev RNA 2021;12:e1633. [PMID: 33112505 DOI: 10.1002/wrna.1633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
198 Bhinder B, Antczak C, Ramirez CN, Shum D, Liu-Sullivan N, Radu C, Frattini MG, Djaballah H. An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates. Assay Drug Dev Technol 2013;11:173-90. [PMID: 23198867 DOI: 10.1089/adt.2012.475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
199 Chen J, Solomides C, Simpkins F, Simpkins H. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother Pharmacol 2017;79:369-80. [DOI: 10.1007/s00280-016-3225-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
200 Zhang X, Liu D, Hayashida Y, Okazoe H, Hashimoto T, Ueda N, Sugimoto M, Kakehi Y. G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells. Int J Mol Sci 2015;16:24319-31. [PMID: 26473854 DOI: 10.3390/ijms161024319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
201 Guimaraes-Stabili MR, de Medeiros MC, Rossi D, Camilli AC, Zanelli CF, Valentini SR, Spolidorio LC, Kirkwood KL, Rossa C Jr. Silencing matrix metalloproteinase-13 (Mmp-13) reduces inflammatory bone resorption associated with LPS-induced periodontal disease in vivo. Clin Oral Investig 2021;25:3161-72. [PMID: 33140162 DOI: 10.1007/s00784-020-03644-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
202 Lu YJ, Lan YH, Chuang CC, Lu WT, Chan LY, Hsu PW, Chen JP. Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy. Int J Mol Sci 2020;21:E7111. [PMID: 32993166 DOI: 10.3390/ijms21197111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
203 Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res 2011;28:2983-95. [PMID: 22009588 DOI: 10.1007/s11095-011-0604-5] [Cited by in Crossref: 96] [Cited by in F6Publishing: 79] [Article Influence: 9.6] [Reference Citation Analysis]
204 Guo H, Zhu G, Wu C. [Construction and influence of human nuclear factor-κB p65 shRNA lentiviral 
vector on malignant biological behavior of lung cancer cells]. Zhongguo Fei Ai Za Zhi 2014;17:369-77. [PMID: 24854553 DOI: 10.3779/j.issn.1009-3419.2014.05.02] [Reference Citation Analysis]
205 Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta 2014;1846:75-87. [PMID: 24747178 DOI: 10.1016/j.bbcan.2014.04.005] [Cited by in Crossref: 181] [Cited by in F6Publishing: 273] [Article Influence: 25.9] [Reference Citation Analysis]
206 Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H, Miyamoto Y. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer 2011;47:452-9. [PMID: 20965717 DOI: 10.1016/j.ejca.2010.09.028] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
207 Kieckhaefer JE, Maina F, Wells RG, Wangensteen KJ. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. Semin Liver Dis 2019;39:261-74. [PMID: 30912094 DOI: 10.1055/s-0039-1678725] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
208 Yang X, Ye T, Liu H, Lv P, Duan C, Wu X, Jiang K, Lu H, Xia D, Peng E, Chen Z, Tang K, Ye Z. Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Mol Cancer 2021;20:4. [PMID: 33397425 DOI: 10.1186/s12943-020-01300-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
209 Monty MA, Islam MA, Nan X, Tan J, Tuhin IJ, Tang X, Miao M, Wu D, Yu L. Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy. Br J Pharmacol 2021;178:1741-55. [PMID: 33608889 DOI: 10.1111/bph.15414] [Reference Citation Analysis]
210 Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, Vecellio M, Russo S, Cogliati F, Larizza L, Ropers HH, Tzschach A, Kalscheuer V, Oehl-Jaschkowitz B, Skinner C, Schwartz CE, Gecz J, Van Esch H, Raynaud M, Chelly J, de Brouwer AP, Toniolo D, D'Adamo P. Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. Am J Hum Genet 2010;86:185-95. [PMID: 20159109 DOI: 10.1016/j.ajhg.2010.01.011] [Cited by in Crossref: 157] [Cited by in F6Publishing: 136] [Article Influence: 14.3] [Reference Citation Analysis]
211 Driver JP, Chen YG, Mathews CE. Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes. Rev Diabet Stud 2012;9:169-87. [PMID: 23804259 DOI: 10.1900/RDS.2012.9.169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
212 Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, Riazuddin S, Hassan S. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv. 2010;28:27-34. [PMID: 19729057 DOI: 10.1016/j.biotechadv.2009.08.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
213 Swaminathan S, Murray DD, Kelleher AD. miRNAs and HIV: unforeseen determinants of host-pathogen interaction. Immunol Rev 2013;254:265-80. [PMID: 23772625 DOI: 10.1111/imr.12077] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
214 Choi SH, Park JY. Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. Cancer Cell Int. 2017;17:3. [PMID: 28053598 DOI: 10.1186/s12935-016-0374-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
215 Hagopian JC, Hamil AS, van den Berg A, Meade BR, Eguchi A, Palm-Apergi C, Dowdy SF. Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers. Nucleic Acid Ther 2017;27:260-71. [PMID: 28933656 DOI: 10.1089/nat.2017.0686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
216 Fathabadi EG, Shelling AN, Al-kassas R. Nanocarrier systems for delivery of siRNA to ovarian cancer tissues. Expert Opinion on Drug Delivery 2012;9:743-54. [DOI: 10.1517/17425247.2012.683173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
217 Ruigrok MJR, Frijlink HW, Melgert BN, Olinga P, Hinrichs WLJ. Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Mol Ther Methods Clin Dev 2021;20:483-96. [PMID: 33614824 DOI: 10.1016/j.omtm.2021.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, Simonis J, Kompella UB, Ambati BK. Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 2012;53:2837-44. [PMID: 22467572 DOI: 10.1167/iovs.11-9139] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
219 Hastings ML, Brigande JV. Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction. Hear Res 2020;394:107931. [PMID: 32173115 DOI: 10.1016/j.heares.2020.107931] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
220 Rao DD, Senzer N, Wang Z, Kumar P, Jay CM, Nemunaitis J. Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application. Methods Mol Biol 2013;942:259-78. [PMID: 23027056 DOI: 10.1007/978-1-62703-119-6_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
221 Tsai CK, Huang LC, Tsai WC, Huang SM, Lee JT, Hueng DY. Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas. Oncotarget 2018;9:15705-20. [PMID: 29644003 DOI: 10.18632/oncotarget.24594] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
222 Ragusa M, Barbagallo C, Statello L, Condorelli AG, Battaglia R, Tamburello L, Barbagallo D, Di Pietro C, Purrello M. Non-coding landscapes of colorectal cancer. World J Gastroenterol. 2015;21:11709-11739. [PMID: 26556998 DOI: 10.3748/wjg.v21.i41.11709] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
223 Hsu S, Huang G, Ho T, Feng F. Efficient Gene Silencing in Mesenchymal Stem Cells by Substrate-Mediated RNA Interference. Tissue Engineering Part C: Methods 2014;20:916-30. [DOI: 10.1089/ten.tec.2013.0780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
224 Zimmer AM, Pan YK, Chandrapalan T, Kwong RWM, Perry SF. Loss-of-function approaches in comparative physiology: is there a future for knockdown experiments in the era of genome editing? J Exp Biol 2019;222:jeb175737. [PMID: 30948498 DOI: 10.1242/jeb.175737] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 9.5] [Reference Citation Analysis]
225 Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, Norollahi SE, Samadani AA. An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci. 2020;240:117077. [PMID: 31751586 DOI: 10.1016/j.lfs.2019.117077] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
226 Fujii H, Matkar P, Liao C, Rudenko D, Lee PJ, Kuliszewski MA, Prud'homme GJ, Leong-Poi H. Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy. Mol Ther Nucleic Acids 2013;2:e94. [PMID: 23695537 DOI: 10.1038/mtna.2013.20] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
227 Zheng H, Tang C, Yin C. Oral delivery of shRNA based on amino acid modified chitosan for improved antitumor efficacy. Biomaterials 2015;70:126-37. [DOI: 10.1016/j.biomaterials.2015.08.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
228 Hu B, Meng X, Zhang Y, Hossain MM, Wu L, Zhang Y, Peng X, Zhang X. Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action. Oncol Rep 2018;39:1640-8. [PMID: 29393483 DOI: 10.3892/or.2018.6237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
229 Mukerjee A, Shankardas J, Ranjan AP, Vishwanatha JK. Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology 2011;22:445101. [PMID: 21990205 DOI: 10.1088/0957-4484/22/44/445101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
230 Ghatak S, Markwald RR, Hascall VC, Dowling W, Lottes RG, Baatz JE, Beeson G, Beeson CC, Perrella MA, Thannickal VJ, Misra S. Transforming growth factor β1 (TGFβ1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts. J Biol Chem 2017;292:10465-89. [PMID: 28389562 DOI: 10.1074/jbc.M116.752451] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
231 Stegh AH. Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) 2013;5:48-65. [PMID: 22858688 DOI: 10.1039/c2ib20104f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
232 Shpak N, Manor R, Abilevich LK, Mantal O, Shavit K, Aflalo ED, Toiber D, Sagi A. Short versus long double-stranded RNA activation of a post-transcriptional gene knockdown pathway. RNA Biol 2017;14:1766-75. [PMID: 28816598 DOI: 10.1080/15476286.2017.1356567] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
233 Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med. 2010;12:e26. [PMID: 20716384 DOI: 10.1017/S1462399410001584] [Cited by in Crossref: 38] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
234 Bhinder B, Shum D, Li M, Ibáñez G, Vlassov AV, Magdaleno S, Djaballah H. Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens. PLoS One 2014;9:e100676. [PMID: 24987961 DOI: 10.1371/journal.pone.0100676] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
235 Deng J, Chen S, Wang F, Zhao H, Xie Z, Xu Z, Zhang Q, Liang P, Zhai X, Cheng Y. Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival. Mol Neurobiol 2016;53:1132-44. [PMID: 25586062 DOI: 10.1007/s12035-014-9080-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
236 Lv L, Shi Y, Wu J, Li G. Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting. Int J Nanomedicine 2021;16:1487-508. [PMID: 33654398 DOI: 10.2147/IJN.S282110] [Reference Citation Analysis]
237 Stuart WD, Guo M, Fink-Baldauf IM, Coleman AM, Clancy JP, Mall MA, Lim FY, Brewington JJ, Maeda Y. CRISPRi-mediated functional analysis of lung disease-associated loci at non-coding regions. NAR Genom Bioinform 2020;2:lqaa036. [PMID: 32500120 DOI: 10.1093/nargab/lqaa036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Taghavi S, HashemNia A, Mosaffa F, Askarian S, Abnous K, Ramezani M. Preparation and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells. Colloids Surf B Biointerfaces 2016;140:28-39. [PMID: 26731195 DOI: 10.1016/j.colsurfb.2015.12.021] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
239 Ge Q, Xu JJ, Evans DM, Mixson AJ, Yang HY, Lu PY. Leveraging therapeutic potential of multi-targeted siRNA inhibitors. Future Medicinal Chemistry 2009;1:1671-81. [DOI: 10.4155/fmc.09.131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
240 Yan M, Wen J, Liang M, Lu Y, Kamata M, Chen IS. Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs. PLoS One 2015;10:e0127986. [PMID: 26035832 DOI: 10.1371/journal.pone.0127986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
241 Mohr S, Bakal C, Perrimon N. Genomic screening with RNAi: results and challenges. Annu Rev Biochem. 2010;79:37-64. [PMID: 20367032 DOI: 10.1146/annurev-biochem-060408-092949] [Cited by in Crossref: 203] [Cited by in F6Publishing: 176] [Article Influence: 18.5] [Reference Citation Analysis]
242 Arthanari Y, Pluen A, Rajendran R, Aojula H, Demonacos C. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells. J Control Release 2010;145:272-80. [PMID: 20403398 DOI: 10.1016/j.jconrel.2010.04.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
243 Kowalski PS, Leus NGJ, Scherphof GL, Ruiters MHJ, Kamps JAAM, Molema G. Targeted siRNA delivery to diseased microvascular endothelial cells-Cellular and molecular concepts. IUBMB Life 2011;63:648-58. [DOI: 10.1002/iub.487] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
244 Kaur A, Kumar A, Reddy MS. RNA Interference (RNAi) and Its Role in Crop Improvement: A Review. In: Anis M, Ahmad N, editors. Plant Tissue Culture: Propagation, Conservation and Crop Improvement. Singapore: Springer; 2016. pp. 379-94. [DOI: 10.1007/978-981-10-1917-3_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
245 Shen S, Yu N, Xu H, Liu X, Tan G, Wang Z. Inhibition of Human Glioma Cell Proliferation Caused by Knockdown of Utrophin Using a Lentivirus-Mediated System. Cancer Biotherapy and Radiopharmaceuticals 2016;31:133-8. [DOI: 10.1089/cbr.2015.1939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
246 Simmons O, Maples PB, Senzer N, Nemunaitis J. Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. ISRN Oncol 2012;2012:247657. [PMID: 22523703 DOI: 10.5402/2012/247657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
247 Lenz S, Karsten P, Schulz JB, Voigt A. Drosophila as a screening tool to study human neurodegenerative diseases. J Neurochem 2013;127:453-60. [PMID: 24028575 DOI: 10.1111/jnc.12446] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
248 Coutinho MF, Santos JI, Matos L, Alves S. Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders. Diseases 2016;4:E33. [PMID: 28933412 DOI: 10.3390/diseases4040033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
249 Howard TP, Vazquez F, Tsherniak A, Hong AL, Rinne M, Aguirre AJ, Boehm JS, Hahn WC. Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol 2016;81:237-46. [PMID: 27815544 DOI: 10.1101/sqb.2016.81.031070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
250 Shahbazi R, Ozpolat B, Ulubayram K. Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond) 2016;11:1287-308. [PMID: 27102380 DOI: 10.2217/nnm-2016-0035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
251 Andey T, Marepally S, Patel A, Jackson T, Sarkar S, O'Connell M, Reddy RC, Chellappan S, Singh P, Singh M. Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. J Control Release 2014;184:67-78. [PMID: 24727000 DOI: 10.1016/j.jconrel.2014.03.049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
252 Tung J, Tew LS, Hsu YM, Khung YL. A novel 4-arm DNA/RNA Nanoconstruct triggering Rapid Apoptosis of Triple Negative Breast Cancer Cells within 24 hours. Sci Rep 2017;7:793. [PMID: 28400564 DOI: 10.1038/s41598-017-00912-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
253 de Bruyns A, Geiling B, Dankort D. Construction of Modular Lentiviral Vectors for Effective Gene Expression and Knockdown. In: Federico M, editor. Lentiviral Vectors and Exosomes as Gene and Protein Delivery Tools. New York: Springer; 2016. pp. 3-21. [DOI: 10.1007/978-1-4939-3753-0_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
254 Torrecilla J, Rodríguez-Gascón A, Solinís MÁ, del Pozo-Rodríguez A. Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int 2014;2014:161794. [PMID: 25184135 DOI: 10.1155/2014/161794] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
255 Rao DD, Senzer N, Cleary MA, Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther 2009;16:807-9. [DOI: 10.1038/cgt.2009.53] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
256 Jebelli A, Baradaran B, Mosafer J, Baghbanzadeh A, Mokhtarzadeh A, Tayebi L. Recent developments in targeting genes and pathways by RNAi-based approaches in colorectal cancer. Med Res Rev 2021;41:395-434. [PMID: 32990372 DOI: 10.1002/med.21735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Wieckowski MR, Deus CM, Couto R, Oparka M, Lebiedzińska‐arciszewska M, Duszyński J, Oliveira PJ. Measuring p66Shc Signaling Pathway Activation and Mitochondrial Translocation in Cultured Cells. Current Protocols in Toxicology 2015;66. [DOI: 10.1002/0471140856.tx2506s66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
258 Denise H, Moschos SA, Sidders B, Burden F, Perkins H, Carter N, Stroud T, Kennedy M, Fancy SA, Lapthorn C, Lavender H, Kinloch R, Suhy D, Corbau R. Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision. Mol Ther Nucleic Acids 2014;3:e145. [PMID: 24496437 DOI: 10.1038/mtna.2013.73] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
259 Li G, Tian X, Lv D, Zhang L, Zhang Z, Wang J, Yang M, Tao J, Ma T, Wu H, Ji P, Wu Y, Lian Z, Cui W, Liu G. NLRP7 is expressed in the ovine ovary and associated with in vitro pre-implantation embryo development. Reproduction 2019;158:415-27. [PMID: 31505467 DOI: 10.1530/REP-19-0081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
260 Guo D, Wang B, Han F, Lei T. RNA interference therapy for glioblastoma. Expert Opin Biol Ther 2010;10:927-36. [PMID: 20415602 DOI: 10.1517/14712598.2010.481667] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
261 Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2:305-15. [PMID: 20135697 DOI: 10.1002/wnan.81] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
262 Ding GB, Meng X, Yang P, Li B, Stauber RH, Li Z. Integration of Polylactide into Polyethylenimine Facilitates the Safe and Effective Intracellular siRNA Delivery. Polymers (Basel) 2020;12:E445. [PMID: 32074943 DOI: 10.3390/polym12020445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
263 Han ZX, Wang HM, Jiang G, Du XP, Gao XY, Pei DS. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2. Cancer Biother Radiopharm 2013;28:398-405. [PMID: 23496232 DOI: 10.1089/cbr.2012.1323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
264 Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers. Pharmaceutics 2018;10:E65. [PMID: 29861465 DOI: 10.3390/pharmaceutics10020065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
265 Riehl BD, Lee JS, Ha L, Lim JY. Fluid-flow-induced mesenchymal stem cell migration: role of focal adhesion kinase and RhoA kinase sensors. J R Soc Interface 2015;12:20141351. [PMID: 25589570 DOI: 10.1098/rsif.2014.1351] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
266 Taghavi S, Nia AH, Abnous K, Ramezani M. Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells. Int J Pharm 2017;516:301-12. [PMID: 27840158 DOI: 10.1016/j.ijpharm.2016.11.027] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 12.6] [Reference Citation Analysis]
267 Liu SV, Fabbri M, Gitlitz BJ, Laird-Offringa IA. Epigenetic therapy in lung cancer. Front Oncol 2013;3:135. [PMID: 23755372 DOI: 10.3389/fonc.2013.00135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
268 Kotowska-Zimmer A, Pewinska M, Olejniczak M. Artificial miRNAs as therapeutic tools: Challenges and opportunities. Wiley Interdiscip Rev RNA 2021;12:e1640. [PMID: 33386705 DOI: 10.1002/wrna.1640] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 2018;37:107-24. [PMID: 29243000 DOI: 10.1007/s10555-017-9717-6] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 44.0] [Reference Citation Analysis]
270 Ke X, Yang C, Cheng W, Yang YY. Delivery of NF-κB shRNA using carbamate-mannose modified PEI for eliminating cancer stem cells. Nanomedicine 2018;14:405-14. [PMID: 29175597 DOI: 10.1016/j.nano.2017.11.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
271 García-Aranda M, Téllez T, Muñoz M, Redondo M. Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. Anticancer Drugs 2017;28:702-16. [PMID: 28471806 DOI: 10.1097/CAD.0000000000000507] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
272 Laganà A, Acunzo M, Romano G, Pulvirenti A, Veneziano D, Cascione L, Giugno R, Gasparini P, Shasha D, Ferro A, Croce CM. miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 2014;42:5416-25. [PMID: 24627222 DOI: 10.1093/nar/gku202] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
273 Noiman T, Kahana C. A Simple Combined Use of CRISPR-Cas9 and Cre-LoxP Technologies for Generating Conditional Gene Knockouts in Mammalian Cells. CRISPR J 2018;1:278-85. [PMID: 31021220 DOI: 10.1089/crispr.2018.0010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
274 Lai Y, Xu X, Zhu Z, Hua Z. Highly efficient siRNA transfection in macrophages using apoptotic body-mimic Ca-PS lipopolyplex. Int J Nanomedicine 2018;13:6603-23. [PMID: 30425477 DOI: 10.2147/IJN.S176991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
275 Wong NK, Huang CL, Islam R, Yip SP. Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies. J Hematol Oncol 2018;11:131. [PMID: 30466456 DOI: 10.1186/s13045-018-0673-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
276 Haque S, Kodidela S, Gerth K, Hatami E, Verma N, Kumar S. Extracellular Vesicles in Smoking-Mediated HIV Pathogenesis and their Potential Role in Biomarker Discovery and Therapeutic Interventions. Cells 2020;9:E864. [PMID: 32252352 DOI: 10.3390/cells9040864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
277 Martínez-Negro M, Guerrero-Martínez A, García-Río L, Domènech Ò, Aicart E, Tros de Ilarduya C, Junquera E. Multidisciplinary Approach to the Transfection of Plasmid DNA by a Nonviral Nanocarrier Based on a Gemini-Bolaamphiphilic Hybrid Lipid. ACS Omega 2018;3:208-17. [PMID: 30023772 DOI: 10.1021/acsomega.7b01657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
278 Lyu YS, Shi PL, Chen XL, Tang YX, Wang YF, Liu RR, Luan XR, Fang Y, Mei RH, Du ZF, Ke HP, Matro E, Li LE, Lin ZY, Zhao J, Gao X, Zhang XN. A Small Indel Mutant Mouse Model of Epidermolytic Palmoplantar Keratoderma and Its Application to Mutant-specific shRNA Therapy. Mol Ther Nucleic Acids 2016;5:e299. [PMID: 27003758 DOI: 10.1038/mtna.2016.17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
279 Pietola L. Effects of p27 Kip1 - and p53- shRNAs on kanamycin damaged mouse cochlea. WJO 2012;2:1. [DOI: 10.5319/wjo.v2.i1.1] [Reference Citation Analysis]
280 Cui J, Gong Z, Shen HM. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. Biochim Biophys Acta. 2013;1836:15-26. [PMID: 23428608 DOI: 10.1016/j.bbcan.2013.02.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
281 Lolli A, Colella F, De Bari C, van Osch GJVM. Targeting anti‐chondrogenic factors for the stimulation of chondrogenesis: A new paradigm in cartilage repair. J Orthop Res 2018;37:12-22. [DOI: 10.1002/jor.24136] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
282 Jan AT, Rahman S, Badierah R, Lee EJ, Mattar EH, Redwan EM, Choi I. Expedition into Exosome Biology: A Perspective of Progress from Discovery to Therapeutic Development. Cancers (Basel) 2021;13:1157. [PMID: 33800282 DOI: 10.3390/cancers13051157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]